| 3.05 -0.19 (-5.86%) | 06-16 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Obalon Therapeutics, Inc. operates as a fully integrated medical device enterprise, concentrating its efforts on creating and commercializing innovative solutions for individuals battling obesity. The company's flagship offering is the Obalon Balloon System, specifically engineered to promote weight reduction in obese patients. This comprehensive system incorporates an ingestible capsule that houses an inflatable balloon connected to a microcatheter. It also includes the Obalon Navigation System console, a specialized hardware and software platform used to precisely monitor and display the balloon's location during its placement. Further components are the Obalon Touch Inflation Dispenser, a semi-automated, portable instrument for inflating the balloon once it's correctly positioned, and a single-use canister containing a gas mixture. By February 27, 2020, Obalon Therapeutics managed three company-owned treatment centers situated in California. The firm was established in 2008 and bases its operations in Carlsbad, California.
Tue, 19 Aug 2025
Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D - Business Wire
Fri, 01 Dec 2023
ReShape and Obalon Merge in All-Stock Transaction - Medical Device and Diagnostic industry
Sat, 29 Jul 2023
Jonah Shacknai Net Worth (2026) - GuruFocus
Tue, 06 Aug 2019
Obalon Therapeutics Inc. Announces Closing of $16.6 Million Public Offering - GlobeNewswire
Thu, 23 May 2019
Mid-Day Market Update: Crude Oil Down Over 5%; S&W Seed Shares Spike Higher - FXStreet
Fri, 21 Dec 2018
Obalon Announces FDA Approval of Obalon Navigation System - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|